Your browser doesn't support javascript.
loading
[177Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid.
Al-Ibraheem, Akram; Abdlkadir, Ahmed; Al-Adhami, Dhuha; Herrmann, Ken.
Affiliation
  • Al-Ibraheem A; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan; aibraheem@khcc.jo.
  • Abdlkadir A; School of Medicine, University of Jordan, Amman, Jordan.
  • Al-Adhami D; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Herrmann K; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
J Nucl Med ; 65(9): 1494, 2024 Sep 03.
Article in En | MEDLINE | ID: mdl-38754958
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Carcinoid Tumor / Octreotide / Neuroendocrine Tumors / Kidney Neoplasms Limits: Female / Humans / Male / Middle aged Language: En Journal: J Nucl Med Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Carcinoid Tumor / Octreotide / Neuroendocrine Tumors / Kidney Neoplasms Limits: Female / Humans / Male / Middle aged Language: En Journal: J Nucl Med Year: 2024 Document type: Article Country of publication: